Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials -

Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials
Information type: Other primary research
Source: The Lancet Infectious Diseases
Specialities: Infection and infectious diseases | Respiratory disorders
Summary
Analysis (n=6485) found in patients without a contraindication, rifampicin is likely to be the safest latent tuberculosis infection treatment option and safer than isoniazid.
UKMi comment

Authors of a related commentary state if active tuberculosis has been excluded, monotherapy with rifampicin is also likely to be more effective than isoniazid given the greater prevalence of isoniazid mono-resistance than rifampicin-resistant or multidrug-resistant tuberculosis. Authors state isoniazid therapy should only be considered in patients for whom rifampicin has potential for important drug–drug interactions.
Related links: Commentary